Exp Neurobiol.  2014 Sep;23(3):246-252. 10.5607/en.2014.23.3.246.

Increasing the Efficiency of Parkinson's Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System

• Gambaryan
• Kondrasheva IG
• Severin ES
• Guseva AA
• Kamensky A

• KMID: 2165529
• DOI: http://doi.org/10.5607/en.2014.23.3.246

Abstract

To compare the efficacy of L-DOPA administered intranasally in the form of nanoparticles (nano-DOPA) and in standard drug forms using a rat Parkinson's Disease (PD) model. L-DOPA-containing nanoparticles (250+/-50 nm) were synthesized using the double emulsion method. The efficacy of nano-DOPA therapy was studied in Wistar rats with 6-OHDA-induced PD. Drugs were administered daily, 0.35 mg/kg (by L-DOPA). Animals' motor coordination and behavior were analyzed using the forelimb placing task and several other tests. Thirty minutes after the first administration, animals treated with L-DOPA, L-DOPA+benserazide, and nano-DOPA showed equally significant (p<0.05) improvements in coordination performance in comparison to the non-treated group. After 4 weeks of treatment, coordination performance in the nano-DOPA group (89+/-13% of the intact control level) was twice as high as in the L-DOPA and L-DOPA+benserazide groups, which did not differ from non-treated animals. The effect of nano-DOPA was significantly higher and more long-lasting (90+/-13% at 24 h after administration); moreover, it was still significant one week after the treatment was discontinued. Intranasal nano-DOPA was found to provide a lasting motor function recovery in the 6-OHDA-induced rat PD model with the effect sustained for one week after discontinuation, while the same doses of standard drugs provided significant effect only after the first administration. L-DOPA administered in the form of PLGA-based nanoparticles had a higher effective half-life, bioavailability, and efficacy; it was also efficiently delivered to the brain by intranasal administration.

Keyword

animal models; L-DOPA; Parkinson's disease; nano-DOPA; PLGA; nasal administration

MeSH Terms

Administration, Intranasal
Animals
Biological Availability
Brain
Forelimb
Half-Life
Levodopa*
Models, Animal
Nanoparticles
Parkinson Disease*
Rats
Rats, Wistar
Recovery of Function
Levodopa